BioAge Labs (NASDAQ:BIOA) Shares Up 4.6% – Should You Buy?

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) rose 4.6% during mid-day trading on Tuesday . The company traded as high as $16.08 and last traded at $16.04. Approximately 105,106 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 619,233 shares. The stock had previously closed at $15.34.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BIOA shares. Oppenheimer started coverage on BioAge Labs in a report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective on the stock. BTIG Research started coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price for the company. Needham & Company LLC initiated coverage on BioAge Labs in a research report on Friday, March 27th. They issued a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Finally, Piper Sandler assumed coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

BioAge Labs Trading Up 7.6%

The firm has a 50-day simple moving average of $18.05 and a two-hundred day simple moving average of $15.93. The company has a market capitalization of $733.65 million, a price-to-earnings ratio of -6.88 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Equities research analysts anticipate that BioAge Labs, Inc. will post -2.59 EPS for the current year.

Hedge Funds Weigh In On BioAge Labs

Institutional investors have recently made changes to their positions in the company. CWM LLC lifted its stake in shares of BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs in the third quarter worth about $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of BioAge Labs during the 4th quarter worth about $77,000. Nisa Investment Advisors LLC grew its position in shares of BioAge Labs by 4,219.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after acquiring an additional 10,000 shares during the period. Finally, Bank of Nova Scotia purchased a new position in shares of BioAge Labs in the 1st quarter valued at about $180,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.